Rare Journeys
Real Impact

Providing bespoke end-to-end commercialisation solutions for rare disease innovators launching medicines in Europe.

A selection of our trusted partners

A complete end-to-end solution made for the rare disease product lifecycle

Designed for biotech and pharmaceutical firms, our innovative commercialisation solution simplifies the complex issues involved in multi-market drug launches.

Rare diseases focus

Rare diseases focus

We drive treatment access for conventionally underserved patient groups with high unmet needs.

European footprint

European footprint

We deliver market knowledge and infrastructure to launch products in over 16 European markets.

Tailored solutions

Tailored solutions

We combine decades of industry experience from big pharma to life science consultancy.

Deep expertise

Deep expertise

We scope each program to align with the unique requirements and strategy of our partners.

Novel therapies

Accelerate launch trajectories

A comprehensive suite of services designed specifically to support the end-to-end commercialisation needs of biotech and pharmaceutical companies focused on orphan drug development.

Established brands

Optimise multi-market operations

A selection of services to enable secure access to local markets in a time and resource-efficient manner, including multi-market tender and supply chain management.

16

Markets across Europe

11

Life-changing therapies

7

Partners and counting

Ready to take the next step?

Let us share how we could successfully support your product commercialisation.

Therapeutic areas

Genetic & Metabolic Disorders

Our commercialisation expertise spans a range of genetic & metabolic disorders and conditions.

Haematology & Oncology

Within haematology, we work with products and therapies serving a handful of key rare diseases.

CNS & Neurology

Our experience also extends to rare, hereditary disorders affecting the central nervous system.

Latest insights

Stay abreast of key issues and critical thinking within the European rare disease community.

Launching pharmaceuticals in Belgium, the Netherlands, and Luxembourg: opportunities and challenges
Improving health equity in Europe’s small countries: how can we remove the barriers to access?
Launching pharmaceuticals in the Nordics: opportunities and challenges